Fig. 1
From: Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
Time course of HOMA-IR, RLP-C and log[hsCRP] in patients treated with EMPA (triangles, red line) or placebo (circles, black line). Data are presented as mean ± SD. Group differences parameters between baseline and 12 months later between placebo and EMPA were analyzed *p < 0.05 (repeated measures ANOVA); p = 0.0163, p = 0.029 and p = 0.00706 for HOMA-IR, RLP-C and hsCRP, respectively